Trial ISRCTN85216856
Publication Baldeon ME, Transfus Med (2022) (published paper)
Primary outcome on the report: Survival rate before 28 days since onset of plasma transfusion treatment.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.